Citations 2
Self-reported geriatric impairments and treatment toxicity in older patients with multiple myeloma
Abdallah, Nadine , Marar, Rosalyn, Yee, Claire , Bodily, Anna, Truman, Mia, Wildes, Tanya, Weivoda, Megan , Aug, Sarah, Smith, Byron, Kapoor, Prashant , Hayman, Suzanne R. , Dingli, David, Gonsalves, Wilson I, Zanwar, Saurabh , Kourelis, Taxiarchis , Warsame, Rahma , Lin, Yi, Rajkumar, S Vincent, Kumar, Shaji , Yee, Claire , Menser, Terri , Weivoda, Megan , Buadi, Francis K , Dispenzieri, Angela , Cook, Joselle M , Zanwar, Saurabh S , Binder, Moritz , Kourelis, Taxiarchis , Gertz, Morie A , Warsame, Rahma , Dueck, A. C. , Kumar, Shaji K , Wildes, Tanya M. , Buadi, Francis K. , Dispenzieri, Angela , Dingli, David , Gonsalves, Wilson I. , Cook, Joselle , Binder, Moritz , Gertz, Morie A. , Rajkumar, S. Vincent , Dueck, Amylou C.
Blood Advances | July 28, 2026 | Volume: 10 | Issue: 20 | Pages: 6957-6967
10.1182/bloodadvances.2026020579
Abstract Frailty influences treatment outcomes in older patients with multiple myeloma (MM), yet existing frailty tools capture limited geriatric domains and are incompletely studied in the context of contemporary therapies. We prospectively evaluated patient-reported comprehensive geriatric assessment (CGA) domains and their associations with treatment toxicity and patient-reported outcomes (PRO) in older adults with MM. Patients aged ≥60 years with newly diagnosed or relapsed/refractory MM initiating a new therapy completed electronic CGA and PRO questionnaires at baseline and 4 months. Outcomes included clinician- and patient-reported treatment toxicity, treatment adaptations, health care use, and health-related quality of life (HRQOL). A cumulative deficit frailty index (FI) was derived from CGA and HRQOL domains. Among 90 patients (mean age, 72 years), geriatric impairments were common, particularly physical function domains. High-grade nonhematologic toxicities were significantly associated with older age, comorbidities, patient-reported functional limitations, and anxiety. Toxicity rates on the PRO version of the Common Terminology Criteria for Adverse Events (CTCAE) were higher than on CTCAE, highlighting a discordance between physician- and patient-reported treatment toxicity. Frailty was present in 22% and associated with worse baseline HRQOL and increased high-grade nonhematologic toxicity but not treatment adaptations or health care use. Average CGA and HRQOL scores remained stable over 4 months, although individual trajectories varied. Patient-reported geriatric impairments are prevalent in older adults with MM and strongly associated with nonhematologic toxicities even in the contemporary treatment era. Physician-reported CTCAE may not fully reflect patients' symptom burden. Heterogeneity in individual geriatric trajectories during treatment emphasize the need for longitudinal assessment. This study was registered at www.clinicaltrials.gov as NCT05918185.
Biomarkers of Cellular Senescence and their Association with Frailty, Clinical Outcomes, and Survival in Multiple Myeloma
Abdallah, Nadine, White, Thomas, Heeren, Amanda A., Wildes, Tanya, Marar, Rosalyn, Yee, Claire , Bodily, Anna, Kotajarvi, Brian R., Aug, Sarah, Kapoor, Prashant , Dispenzieri, Angela, Hayman, Suzanne, Dingli, David, Gonsalves, Wilson, Cook, Joselle, Zanwar, Saurabh , Lin, Y., Kourelis, Taxiarchis, Gertz, MA, Warsame, Rahma, Rajkumar, S, LeBrasseur, Nathan, Kumar, Shaji, Weivoda, Megan , Abdallah, Nadine H , Heeren, Amanda, Marar, Rosalyn , Yee, Claire , Kotajarvi, Brian, Buadi, Francis K , Kapoor, Prashant , Dispenzieri, Angela , Dingli, David , Gonsalves, Wilson , Cook, Joselle M , Zanwar, Saurabh S , Binder, Moritz , Lin, Yi , Kourelis, Taxiarchis , Gertz, Morie A , Rajkumar, S Vincent , Sfeir, Jad G , Kumar, Shaji K , Weivoda, Megan , Abdallah, Nadine , Smith, Byron H. , Wildes, Tanya M. , Buadi, Francis K. , Dispenzieri, Angela , Hayman, Suzanne, Dingli, David , Gonsalves, Wilson I. , Cook, Joselle , Binder, Moritz , Kourelis, Taxiarchis , Warsame, Rahma , Sfeir, Jad , LeBrasseur, Nathan K
No container title available | March 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available
Abstract Frailty predicts adverse outcomes in multiple myeloma (MM), yet an objective frailty biomarker is lacking. Circulating senescence-associated secretory phenotype (SASP) factors correlate with frailty and adverse outcomes in chronic diseases, but their relevance in MM is unclear. In this study, we investigated the relationship between 36 plasma SASP factors, frailty, and clinical outcomes in: (1) a historical cohort using stored specimens from 59 patients with newly diagnosed MM, and (2) a prospective cohort of 36 patients initiating new MM treatment. Several SASP factors were significantly associated with frailty after adjusting for age, sex, and body mass index; GDF-15, TNF-RI, IL-6, and IL-8 showed positive correlations with both cumulative-deficit based and physical frailty indices. Additionally, significant age-adjusted associations were observed between SASP factors and treatment outcomes, including overall survival (OS), high-grade toxicity, and healthcare utilization. We developed a 5-factor SASP model that demonstrated superior predictive performance for OS compared to chronological age, R-ISS stage, and clinical frailty, and TNF-RI alone (5-year OS AUC: 0.90). These findings highlight the association between senescence biomarkers and frailty and OS, and support further investigation of SASP factors as objective frailty biomarkers in MM.